Original Research Article

Assessment of Liver function tests and its correlation with inflammatory markers and severity of disease during COVID-19 second wave in a tertiary care centre

ABSTRACT

Aims: To assess the Liver function tests in COVID-19 infection and study its correlation with inflammatory markers and severity of disease.

Study design: A Retrospective Observational study.

Place and Duration of Study: Government Kilpauk Medical College, Chennai, India. Two month study period was taken during the second COVID wave (1st May 2021 to 30th June 2021).

Methodology: All COVID-19 positive patients who were above 19 years of age were included in the study. Patients with any chronic liver disease, Hepatitis B or Hepatitis C were excluded. Data was collected from case files. Record was made of the liver function tests and inflammatory markers – C-Reactive Protein and Interleukin-6 (CRP, IL-6). Severe disease was defined as patients with respiratory rate > 30/min, SpO2 <90% on room air or requiring Intensive Care Unit (ICU) admission or mechanical ventilation. Collected data was analysed using appropriate statistical tests.

Results: 132 patients were included in the study. Out of these 59 patients (44.70%) had elevated Liver function tests (LFTs). Maximum patients (42.37%) had hepatocellular pattern. 59.32% patients were males. Mean age of patients with elevated LFTs was 51.03±13.03 years. ICU admission was required in 40.68% of patients with deranged LFTs compared to 23.28% in patients with normal LFTs, which was statistically significant (P <.03). A positive correlation was found between deranged LFTs and inflammatory markers (CRP, IL-6). (P <.001).

Conclusion: Abnormal liver function tests are present in a significant number of COVID-19 positive patients. Elevated LFTs show a positive correlation with the inflammatory markers. Severe disease was more common in patients with abnormal liver function tests.

Keywords: COVID-19, liver function test, severe disease, inflammatory markers.

1. INTRODUCTION

COVID-19 pandemic has affected over 350 million people worldwide till now. SARS-CoV-2 is a highly transmissible virus which can spread from person to person through respiratory droplets during sneezing and coughing. The incubation period of the disease is 2-14 days.

SARS-CoV-2 is a member of genus betacoronavirus of the family coronaviridae. Coronavirus is single stranded RNA enveloped virus, of size 62-125 nm. It has four structural proteins known as S (Spike), E (envelope), M (membrane) and N (nucleic acid).

Although COVID-19 patients usually present with respiratory symptoms but involvement of other organ systems have also been reported leading to gastrointestinal symptoms[1] abnormal liver functions[2] and lymphadenopathy[3]. Few studies suggest significant association of SARS-CoV-2 with liver dysfunction or damage. [4,5] The exact pathogenesis of liver injury in SARS-CoV-2 infection remains unclear. Possible mechanism includes direct virus-induced cytopathic effects, exacerbation of pre-existing liver disease, hypoxemia, drug induced, and overshooting inflammatory responses.

It has been postulated that the S protein of SARS-CoV-2 initially binds to the ACE-2 receptors which are found in epithelial cells and tissues of lung, heart, liver, blood vessels, GI tract and kidneys [6] inducing uptake of virus particles.[7,8] ACE-2 receptors are also present in central hepatic vein and portal vein endothelial cells. The binding of SARS-CoV-2 virus to ACE 2 receptors on cholangiocytes may lead to liver dysfunction.[9] Other potential mechanisms include hypoxic changes caused by respiratory failure and drug induced liver injury.[10].

Our study aims to assess the liver function test in COVID-19 infection and to study its correlation with inflammatory markers and severity of disease.

2. MATERIAL AND METHODS

A retrospective observational study was carried out at Government Kilpauk Medical College and Hospital, Chennai, which is a tertiary care centre. The study was carried out over two months period (1st May 2021 to 30th June 2021), during the second COVID wave.

All COVID-19 positive patients who were above 19 years of age were included in the study. Patients with any chronic liver disease, hepatitis B or Hepatitis C were excluded from the study. The COVID-19 infection cases were detected by real-time reverse transcriptase polymerase reaction (RT-PCR) from nasal or pharangeal swab. The study was conducted after approval from Institutional ethics committee. Data was collected from case files. Demographic data (age, gender) was noted. Record was made of the liver function tests and inflammatory markers [C-reactive protein (CRP) and interleukin -6 (IL-6)]. Aspartate aminotransferase (AST) value more than 40 U/L, Alanine aminotransferase (ALT) value more than 40 U/L, alkaline phosphate (ALP) value more than 120 U/L and total bilirubin value more than 1.5 mg/dl were taken as abnormal LFT values. CRP value of more than 5 mg/dl and IL-6 value of 15 pg/ml were considered as elevated inflammatory markers. In the study liver injury was defined as hepatocellular, cholestatic or mixed type by calculating the R factor. Severe disease was defined as patients with respiratory rate > 30/min, SpO2 <90% on room air and requiring ICU admission or mechanical ventilation.

Collected data was tabulated in MS- Excel. The data was analysed using appropriate statistical tests. Demographic variables were expressed as percentage. Correlation analysis was done by using the Pearson correlation coefficient. *P* value of <.05 was considered as statistically significant.

3. RESULTS AND DISCUSSION

132 patients were included in the study who fulfilled our inclusion criteria.

Out of these 59 patients (44.70%) had elevated Liver function tests and the rest 73 had normal LFTs. (Figure 1) Our findings were consistent to other studies like study by Saini RK *et al* [4] and Priyadarshini BP *et al* [11] which also suggest that COVID -19 is associated with liver dysfunction in a significant number of patients. Another Indian study showed that more than half of patients of COVID-19 have several liver function tests abnormalities. [12]



Figure 1 – Percentage of COVID-19 patients with and without deranged LFTs

3.1 Demographic profile

Of all the total patients included in the study, 58.33% were males and 41.67% were females.
The pattern of LFT profile amongst the males and females is shown in Figure 2. Amongst the patients who had deranged LFTs, 59.32% patients were males and 40.68% were females.



Figure 2- Pattern of LFTs according to Gender

Similar to our study, few other studies (Saini RK *et al.*[4] and Priyadarshini BP *et al.*[11]) also found a slight male preponderance for COVID-19 infection. Another study done in India by Kaushik A et al reported the percentage of male and females were 60.9 and 39% respectively.[12] A slightly increased predominance amongst the males according to some studies in Wuhan is attributed to higher expression of ACE-2 receptors in males. [13,14]

Fan et al reported mean age of 50 years (36-44) among 148 patients with COVID-19 cases.[15]
In our study, mean age of patients was 47.52 ± 12.06 years in those with normal LFTs and 51.03 ± 13.03 years in those with elevated LFTs. (Table 1).

3.2 Liver injury in COVID-19 infection

Amongst the patients with deranged LFTs, maximum patients (42.37%) had hepatocellular pattern of type of liver injury, followed by mixed pattern in 37% and cholestatic pattern was seen only in 20 %. (Figure 3)



Figure 3 – Type of Liver injury

A study by Xu W et al also showed that the pattern of abnormal liver function tests is predominantly hepatocellular.[16] Cai Q *et al* however found mixed type of liver injury to be most common.[17]

Mean LFTs values amongst those with elevated LFTs were as follows- Mean S. Bilirubin = 3.26 ± 1.03 mg/dl, Mean AST = 195.29 ± 102.71 IU/L, Mean ALT = 211.75 ± 106.89 IU/L, Mean ALP = 177.51 ± 61.42.
On calculating the mean values of the different parameters of LFTs in the 2 groups, it was observed that the elevation in the liver function tests was significant (Table1)

Table 1- Comparison of normal LFTs and Deranged LFTs group in COVID-19 patients

PARAMETERS	**NORMAL LFTs GROUP (N=73)**	**DERANGED LFTs GROUP (N=59)**	***P*-value**
Mean age (years)	47.52 ± 12.06	51.03 ± 13.30	.54 (NS)
MeanS.Bilirubin (mg/dl)	0.80 ± 0.18	3.26 ± 1.03	<.001 (S)
Mean AST (IU/L)	29.14 ± 6.48	195.29 ± 102.71	<.001 (S)
Mean ALT (IU/L)	32.68 ± 6.15	211.75 ± 106.89	<.001 (S)
Mean ALP	77.37 ± 15.70	177.51 ± 61.42	<.001 (S)

Patients with severe COVID-19 have higher bilirubin levels compared with those with milder forms. [18]
Total bilirubin was found to be significantly increased (*P* <.001) in patients with abnormal liver enzyme levels and liver injury as compared to patients with normal liver enzyme levels.[4]
In study by Saini RK *et al*., he found, median values of AST, ALT, ALP were found to be 95.0 U/L, 127.7 U/L, 142.0 U/L. [4].

The inflammatory markers were raised significantly. Mean IL-6 was 17.07 ± 13.16 pg/ml and Mean CRP was 18.7 ± 13.7 mg/dl in patients with deranged LFTs.

3.3 Correlation of LFTs with severity of disease and inflammatory markers

Severe disease was defined as patients with respiratory rate > 30/min, SpO2 <90% on room air and requiring ICU admission or mechanical ventilation. ICU admission was required in 40.68% of patients with deranged LFTs compared to 23.28% in patients with normal LFTs, which was statistically significant (*P* <.03) (Figure 4).
Among the patients with deranged LFTs, 4 patients expired (6.7%), whereas only 2 deaths (2.7%) were reported in patients with normal LFTs.



Figure 4 – Percentage of ICU admissions

RK Saini also conducted a study in which he found 37.07% patients with elevated LFTs and 21.15% with normal LFTs required ICU admissions. [4]

On calculating the *P*-values amongst the different liver function tests and the CRP and IL-6 values in the group with deranged LFTs, a positive correlation was found between deranged LFTs and inflammatory markers (CRP, IL-6). (*P*<.001). (Figure 5,6)

Our results were consistent with studies by Saini RK et al and Xu W et al who also concluded that patients with abnormal LFTs are at an increased risk of severe disease.[4,16] Also Saini RK et al in their study concluded that patients with abnormal LFTs were associated with raised levels of inflammatory markers and they found a positive correlation between elevated LFTs and CRP.[4]



Figure 5- Correlation of LFTs with IL-6



Figure 6- Correlation of LFTs with CRP

Management

All the patients were treated according to the COVID-19 protocol guidelines issued by ministry of health and family welfare, Government of India.

4. CONCLUSION

COVID-19 patients usually present with respiratory symptoms but involvement of other organ systems have also been reported.
Abnormal liver function tests are present in a significant number of COVID-19 positive patients. Elevated LFTs show a positive correlation with the inflammatory markers. Severe disease requiring ICU admission was more common in patients with abnormal liver function tests.

REFERENCES

1. To KF, Tong JH, Chan PK, Au FW, Chim SS, Allen Chan KC, *et al.* Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases. J Pathol 2004;202(2):157–63.
2. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, *et al.* Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319–25.
3. Ding Y, Wang H, Shen H, Li Z, Geng J, Han H, *et al.* The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol 2003;200:282–9.
4. Saini RK, Saini N, Ram S, Soni SL, Suri V, Malhotra P, et al. COVID-19 associated variations in liver function parameters: a retrospective study. Postgrad Med J. 2020;10:1-7.
5. Xu W, Huang C, Fei L, Li Q, Chen L. Dynamic Changes in Liver Function Tests and Their Correlation with Illness Severity and Mortality in Patients with COVID-19: A Retrospective Cohort Study. *Clin Interv Aging*. 2021;16:675-685
6. Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;20:445-17.
7. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-4.
8. Zhou P, Yang XL, Wang XG, Hu Ben, Zhang L, Zhang W, Si HR, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-3.
9. Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, Zhou J, Shi G, Fang N, Fan J, Cai J. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. Bio Rxiv 2020.
10. Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol. 2020;26:2323-32.
11. Priyadarshi BP, Kumar A, Singh V, Varma SK, Yadav R, Pandey P. A clinical profile of liver function tests in COVID-19 patients at tertiary care centre from north India. Int J Res Med Sci 2021;9:2633-8.
12. Kaushik A, Wani SN, Baba MA, Aggarwal AK. Prevalence of Abnormal Liver Function Tests in COVID-19 Patients at a Tertiary Care Centre. JAPI. 2020;68:10-16. 27.
13. Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, Lou Y, Gao D, Yang L, He D, Wang MH. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. Int J Infect Dis 2020;92:214–7.
14. Zhou C. Evaluating new evidence in the early dynamics of the novel coronavirus COVID-19 outbreak in Wuhan, China with real time domestic traffic and potential asymptomatic transmissions. medRxiv 2020.doi: 10.1101/2020.02.15.20023440.
15. Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C. Clinical Features of COVID-19-Related Liver Functional Abnormality. Clin Gastroenterol Hepatol. 2020;18:1561-66.
16. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al . Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:606-12.
17. Qingxian Cai, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. Journal of Hepatol. 2020;73:566-74
18. Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. *Liver Int* 2020; 40:1321–1326.

ABBREVIATIONS

ACE-2	ANGIOTENSIN-CONVERTING ENZYME 2
ALP	ALKALINE PHOSPHATASE
ALT	ALANINE AMINOTRANSFERASE
AST	ASPARTATE AMINOTRANSFERASE
CRP	C REATIVE PROTEIN
ICU	INTENSIVE CARE UNIT
IL-6	INTERLEUKIN-6
LFT	LIVER FUNCTION TESTS
SARS-COV2	SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2